Mesenchymal Stromal Cell-Based Immunotherapy for Type 1 Diabetes: From Bench to Bedside
International Journal of Molecular Sciences · 08.11.2026 · 27 (21) · 10005
DOI: 10.3390/ijms272110005 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 08.11.2026. Verfasst von Alexey Lupatov und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Biomedical Chemistry (IBMC), 119121 Moscow, Russia. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Mesenchymal Stem Cells, Mesenchymal Stem Cell Transplantation, Immunotherapy. Die Arbeit nennt 239 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 1 diabetes mellitus (T1D) is an autoimmune disease characterized by the progressive destruction of pancreatic β-cells. Despite advances in glucose monitoring and insulin delivery, current treatments do not directly target the underlying autoimmune process. The administration of mesenchymal stromal cells (MSCs) represents a promising therapeutic approach due to their immunomodulatory, anti-inflammatory, and regenerative properties. Unlike therapies targeting individual immune pathways, MSCs exert broad immunomodulatory effects. This review integrates current knowledge of T1D immunopathogenesis with evidence on MSC-mediated immunomodulation, highlighting the ability of MSCs to modulate multiple interconnected mechanisms, including innate and adaptive immunity, antigen presentation, inflammatory signaling, and immune tolerance. Preclinical evidence suggests that MSCs may attenuate inflammation, regulate immune responses, preserve β-cell function, and improve metabolic outcomes. A preliminary but encouraging finding from clinical studies is that MSC administration may produce sustained beneficial effects after a limited number of injections. However, this observation remains tentative and requires confirmation in further studies. Standardized treatment protocols, adequately powered controlled trials, and long-term follow-up are needed to establish the clinical efficacy, durability of response, and optimal use of MSC-based therapy in T1D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Biomedical Chemistry (IBMC), 119121 Moscow, Russia.
- Endocrinology Research Centre, 117292 Moscow, Russia.
ORCID-Profile: Irina Pokusaeva, Irina Kholodenko, Marina Shestakova, Rita Khusainova, Ildar Minniakhmetov, Vladimir Chekhonin, Konstantin Yarygin
Förderung
- Ministry of Science and Higher Education of the Russian Federation
Zitieren
APA
Lupatov, A., Pokusaeva, I., Kholodenko, I., Shestakova, M., Larin, K., Khusainova, R., Minniakhmetov, I., Chekhonin, V., Yarygin, K., & Mokrysheva, N. (2026). Mesenchymal Stromal Cell-Based Immunotherapy for Type 1 Diabetes: From Bench to Bedside. International Journal of Molecular Sciences, 27(21), 10005. https://doi.org/10.3390/ijms272110005
Vancouver
Lupatov A, Pokusaeva I, Kholodenko I, Shestakova M, Larin K, Khusainova R, et al. Mesenchymal Stromal Cell-Based Immunotherapy for Type 1 Diabetes: From Bench to Bedside. International Journal of Molecular Sciences. 2026;27(21):10005. doi:10.3390/ijms272110005
BibTeX
@article{Lupatov2026,
author = {Lupatov, Alexey and Pokusaeva, Irina and Kholodenko, Irina and Shestakova, Marina and Larin, Kirill and Khusainova, Rita and Minniakhmetov, Ildar and Chekhonin, Vladimir and Yarygin, Konstantin and Mokrysheva, Natalia},
title = {Mesenchymal Stromal Cell-Based Immunotherapy for Type 1 Diabetes: From Bench to Bedside},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {10005},
doi = {10.3390/ijms272110005}
}
EUVIMED